Cullinan Therapeutics (CGEM) Competitors $8.52 +0.24 (+2.90%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$8.44 -0.07 (-0.88%) As of 05/1/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. GLPG, IDYA, ARQT, TVTX, AGIO, HRMY, EWTX, IRON, INDV, and KNSAShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Galapagos (GLPG), IDEAYA Biosciences (IDYA), Arcutis Biotherapeutics (ARQT), Travere Therapeutics (TVTX), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), Edgewise Therapeutics (EWTX), Disc Medicine (IRON), Indivior (INDV), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Galapagos IDEAYA Biosciences Arcutis Biotherapeutics Travere Therapeutics Agios Pharmaceuticals Harmony Biosciences Edgewise Therapeutics Disc Medicine Indivior Kiniksa Pharmaceuticals Cullinan Therapeutics (NASDAQ:CGEM) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability. Which has stronger earnings & valuation, CGEM or GLPG? Galapagos has higher revenue and earnings than Cullinan Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$153.16M-$3.03-2.81Galapagos$288.19M6.12$80.16MN/AN/A Does the MarketBeat Community prefer CGEM or GLPG? Galapagos received 420 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 83.64% of users gave Cullinan Therapeutics an outperform vote while only 63.75% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformCullinan TherapeuticsOutperform Votes4683.64% Underperform Votes916.36%GalapagosOutperform Votes46663.75% Underperform Votes26536.25% Do analysts prefer CGEM or GLPG? Cullinan Therapeutics currently has a consensus target price of $33.50, indicating a potential upside of 293.19%. Galapagos has a consensus target price of $25.33, indicating a potential downside of 5.40%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cullinan Therapeutics is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Galapagos 4 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media refer more to CGEM or GLPG? In the previous week, Cullinan Therapeutics had 2 more articles in the media than Galapagos. MarketBeat recorded 13 mentions for Cullinan Therapeutics and 11 mentions for Galapagos. Cullinan Therapeutics' average media sentiment score of 1.45 beat Galapagos' score of 0.64 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galapagos 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CGEM or GLPG? Cullinan Therapeutics has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Is CGEM or GLPG more profitable? Galapagos' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -26.54% -25.32% Galapagos N/A N/A N/A Do insiders & institutionals have more ownership in CGEM or GLPG? 86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryCullinan Therapeutics beats Galapagos on 8 of the 14 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$502.81M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-3.0030.0722.5118.54Price / SalesN/A494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book0.803.176.734.25Net Income-$153.16M-$72.35M$3.22B$248.18M7 Day Performance4.67%2.14%1.38%1.03%1 Month Performance8.95%5.67%2.79%2.70%1 Year Performance-69.11%-23.57%15.41%4.05% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics2.6623 of 5 stars$8.52+2.9%$33.50+293.2%-69.7%$502.81MN/A-3.0030Analyst RevisionNews CoveragePositive NewsGLPGGalapagos0.6167 of 5 stars$26.87+0.0%$25.33-5.7%-8.7%$1.77B$288.19M0.001,310Options VolumeHigh Trading VolumeIDYAIDEAYA Biosciences3.7076 of 5 stars$19.75+3.9%$53.58+171.3%-50.3%$1.73B$7M-5.9880Upcoming EarningsPositive NewsHigh Trading VolumeARQTArcutis Biotherapeutics2.757 of 5 stars$14.53-0.5%$18.80+29.4%+65.7%$1.72B$196.54M-8.12150Upcoming EarningsPositive NewsTVTXTravere Therapeutics2.9287 of 5 stars$19.36+5.6%$32.08+65.7%+246.0%$1.72B$233.18M-4.72460Earnings ReportNews CoveragePositive NewsAGIOAgios Pharmaceuticals4.2313 of 5 stars$29.62+0.6%$56.57+91.0%-8.1%$1.70B$36.50M2.61390Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageHRMYHarmony Biosciences4.8214 of 5 stars$29.36-0.8%$52.44+78.6%-1.4%$1.68B$714.73M13.91200Upcoming EarningsAnalyst RevisionPositive NewsEWTXEdgewise Therapeutics3.2126 of 5 stars$15.68+5.7%$40.13+155.9%-12.3%$1.64BN/A-10.4560Upcoming EarningsAnalyst ForecastShort Interest ↑News CoverageIRONDisc Medicine2.3231 of 5 stars$46.16+1.6%$93.80+103.2%+74.1%$1.60BN/A-11.6030Upcoming EarningsNews CoveragePositive NewsINDVIndivior3.3449 of 5 stars$11.57+0.1%$15.00+29.6%-34.5%$1.60B$1.17B-33.061,164Earnings ReportShort Interest ↑Analyst RevisionPositive NewsGap UpKNSAKiniksa Pharmaceuticals2.484 of 5 stars$21.47+0.5%$37.17+73.1%+43.0%$1.56B$423.24M-153.35220Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies GLPG Alternatives IDYA Alternatives ARQT Alternatives TVTX Alternatives AGIO Alternatives HRMY Alternatives EWTX Alternatives IRON Alternatives INDV Alternatives KNSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGEM Stock Free CGEM Stock Alerts